Home » Research Area » » 7-TM Receptors » GPR35 » Zaprinast

Zaprinast

Cat. No. 0947

Price and Availability

For Zaprinast pricing & availability please select your country from the drop down menu:
Submit

By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: 2-(2-Propyloxyphenyl)-8-azapurin-6-one

Biological Activity

Phosphodiesterase inhibitor, selective for PDE6, 5, 11 and 9 (IC₅₀ values are 0.15, 0.76, 12.0 and 29.0 μM respectively). Putative GPR35 agonist.

Technical Data

M.Wt:

271.28

Formula:

C₁₃H₁₃N₅O₂

Solubility:

Soluble to 100 mM in DMSO

Purity:

>99 %

Storage:

Store at RT

CAS No:

37762-06-4

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Resources

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch

Select another batch:

Safety Data Sheet: View Safety Data Sheet

References

Christensen and Torphy (1994) Isozyme-selective phosphodiesterase inhibitors as antiasthmatic agents. Annu.Rep.Med.Chem. 29 185.

Soderling et al (1998) Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J.Biol.Chem. 273 15553. PMID: 9624145.

Lugnier (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol.Ther. 109 366. PMID: 16102838.

Taniguchi et al (2006) Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35. FEBS Lett. 580 5003. PMID: 16934253.

If you know of a relevant citation for this product please let us know.

View Related Products by Target

GPR35

Phosphodiesterases

Keywords: Zaprinast, supplier, PDE5/6/9/11, inhibitors, Phosphodiesterases

Quick Order

Find multiple products by catalog number

7-TM Receptor Signaling

Written by T. Kenakin et al

'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy